Quest Diagnostics Launches COVID-19 Workforce Testing Services

Quest Diagnostics has launched a new suite of Return to Work services built around large-scale workforce COVID-19 testing. The services are designed to help organizations access and act on COVID-19 laboratory insights in order to foster safer workplace environments for their employees as the nation begins to restart the U.S. economy.

Quest Diagnostics is a leading provider of employee population health and workplace drug testing services, serving thousands of employers across the United States. The company’s services range from lab and biometric screening to behavioral and mental health interventions to telemedicine and flu clinics.

To accommodate expected demand, the company is scaling up its COVID-19 lab operations and expects to have capacity to perform approximately 150,000 molecular diagnostic tests a day by the end of June, compared to approximately 80,000 of these tests a day currently. The company also has capacity to perform approximately 200,000 antibody tests a day.

“Employers of all kinds are trying to put programs in place to help protect their employees and customers as we return to work over the coming months. To be more effective, these programs will need to use high quality laboratory-based testing with software applications and analytics along with implementation of worksite safety programs,” said Jay G. Wohlgemuth, MD, senior vice president and chief medical officer, and head of Quest’s Employer Population Health business. “Every workforce has different testing needs depending on the local environment, the type of work, the work environment and interactions with customers for the job category. Our Return to Work solution can be tailored to each organization's unique requirements.”

Among the modular features of the new service suite are:

  • Event hosting that includes on-site temperature checks and respiratory and blood specimen collection by trained Quest Diagnostics staff. (Diagnostic testing is performed on respiratory specimens and antibody testing is performed on blood specimens.)
  • Access to a variety of specimen collection options, ranging from respiratory specimen collection for diagnostic testing to use of the company's 2,200 Patient Service Centers for blood draws for COVID-19 antibody testing.
  • IT solutions that include secure online questionnaires to help direct participants to the appropriate testing (diagnostic or antibody) based on factors such as symptoms and exposure to sick individuals and easy-to-understand results reporting.
  • Access to physician ordering, oversight and telemedicine services.
  • Data integrated with contact tracing and infection control software applications in use by employers.
  • Influenza vaccination services are also provided and will ultimately incorporate SARS CoV-2 vaccines, when available.

For more information, visit

More in News